PAOG $0.10 Potential Pending Medical Cannabis Acquisition Into $14 Billion Market
July 23 2020 - 8:35AM
InvestorsHub NewsWire
July 23, 2020
via NextBigTicker.com
PAO Group, Inc.
(USOTC:
PAOG) announced a management takeover and medical cannabis
strategy revitalization last week that sent the stock soaring
nearly 1000% from $0.0003 to $0.003. The next step in PAOG’s
revitalization strategy has the potential to send the PPS to as
high as $0.10.
The
revitalization involves two pending acquisitions. One
of the acquisitions will give PAOG a treatment for Chronic
Obstructive Pulmonary Disease (COPD) derived from a U.S. patented
cannabis extraction process. The developing drug is
called RespRx and the market
for COPD treatment is anticipated to reach
$14 billion by
2025.
The PAOG PPS has
already broken through its 50 Day and 200 Day Moving Averages
(MA). The 50 Day MA Price has now crossed above 200 Day MA
attracting technical bulls that also enjoy the massive trading
volume.
The PAOG PPS was
over $0.01 in January of 2019 and little is standing in the way of
the PPS rapidly returning to the $0.01
level.
The company has
indicated both acquisitions are expected to be closed by the end of
July. That’s next week. An announcement of the RespRx
acquisition could trigger a
run.
A $100 million
valuation is not exceptional in a market where pre-money
valuations of biotechs easily exceeds $100 million.
OTC trading dynamics might lend to resistance of the PAOG stock
climbing to a $0.10 PPS and $100 million valuation, but then again,
those same OTC trading dynamics could lend
support.
With the PAOG
PPS having already exceeded the $0.01 level in recent history with
less resources and assets under the hood, a PAOG breakthrough over
a penny is a strong
possibility.
GW
Pharmaceuticals (GWPH)
has blazed the trail for cannabis
pharmaceuticals. Frederick
Ferri, CEO of PAOG’s
target medical cannabis acquisition said, "Doctors involved in
research with our extracts have given me feedback that our extracts
are superior to those of GW
Pharmaceuticals.”
PAOG’s target
medical cannabis acquisition, in collaboration
with Beech Tree Labs, Inc. (BTL) conducted a series of in vitro
genomic experiments to evaluate the potential of the target’s
cannabis extracts derived from the subject patented extraction
process in the treatment of respiratory diseases. There are a
significant number of genes associated with COPD and Asthma.
The experiments evaluated the ability of various formulations
to change Asthma or COPD associated gene expressions in human small
airway epithelial cells. A cannabis extract alone
demonstrated remarkable activity in gene arrays by up- or
down-regulating individual genes by as much as 200-fold.
Genes appearing especially sensitive to the introduction of
cannabis extract were associated with inflammation, healing and
cancer inhibition.
According to the
World Health Organization, 65 million people have moderate to
severe COPD with three million deaths annually. The treatment of
COPD is currently estimated to be $5 billion in the
United States and $11
billion worldwide.
Disclaimer:
NextBigTicker.com (NBT) is a
third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur.
Source: www.NextBigTicker.com
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Apr 2024 to May 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about PAO Group Inc (PK) (OTCMarkets): 0 recent articles
More PAO Group Inc (PK) News Articles